SPIA
IOVA icon

Steward Partners Investment Advisory’s Iovance Biotherapeutics IOVA Stock Holding History

Steward Partners Investment Advisory’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.7K Hold
10,497
– – ﹤0.01% 3024
2026
Q1 		$36.8K Hold
10,497
– – ﹤0.01% 2938
2025
Q4 		$28.7K Hold
10,497
– – ﹤0.01% 2973
2025
Q3 		$22.8K Hold
10,497
– – ﹤0.01% 3034
2025
Q2 		$18.1K Sell
10,497
-82
-0.8% -$204 ﹤0.01% 2968
2025
Q1 		$35.2K Sell
10,579
-8,100
-43% -$41.8K ﹤0.01% 2551
2024
Q4 		$138K Buy
18,679
+8,482
+83% +$78.6K ﹤0.01% 1808
2024
Q3 		$95.8K Sell
10,197
-800
-7% -$7.58K ﹤0.01% 1894
2024
Q2 		$88.2K Sell
10,997
-300
-3% -$3.21K ﹤0.01% 1844
2024
Q1 		$167K Buy
11,297
+1,667
+17% +$19.4K ﹤0.01% 1516
2023
Q4 		$78.3K Buy
9,630
+2,400
+33% +$12.6K ﹤0.01% 1792
2023
Q3 		$32.9K Buy
+7,230
New +$47.2K ﹤0.01% 2094
2023
Q1 		– Sell
-100
Closed -$639 – 3364
2022
Q4 		$639 Buy
+100
New +$781 ﹤0.01% 3174

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Steward Partners Investment Advisory's IOVA Position: Q2 2026 in Review

Steward Partners Investment Advisory held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 10,497 shares worth $43.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3024.

Steward Partners Investment Advisory first reported a position in IOVA in Q4 2022 and has held it in 13 quarters since. The position peaked at $167K in Q1 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Steward Partners Investment Advisory held 10,497 shares of Iovance Biotherapeutics worth $43.7K as of Q2 2026.
  • Steward Partners Investment Advisory left its Iovance Biotherapeutics share count unchanged in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3024 holding.
  • Steward Partners Investment Advisory first reported a position in Iovance Biotherapeutics in Q4 2022 and has held it in 13 quarters since.
  • Steward Partners Investment Advisory's Iovance Biotherapeutics position peaked at $167K in Q1 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.